SCHEMBL5386014

SCHEMBL5386014

Cc1cc(N2CCC3(CC2)C(=O)NCN3C(C)C)n2nc(-c3ccccc3Cl)c(-c3ccc(Cl)cc3)c2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HSD17B10 Q99714 4/20 0.46
KMT2A Q03164 3/20 0.44
MEN1 O00255 2/20 0.44
POLB P06746 3/20 0.43
MAPT P10636 4/20 0.42
HPGD P15428 2/20 0.42
SMN1; SMN2 Q16637 2/20 0.42
TP53 P04637 2/20 0.41
CRHR1 P34998 2/20 0.40
KDM4E B2RXH2 1/20 0.39
ALDH1A1 P00352 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
THRB P10828 2/20 0.38
LMNA P02545 1/20 0.38
GAA P10253 1/20 0.38
MAPK1 P28482 1/20 0.38
HTT P42858 1/20 0.38
RXFP1 Q9HBX9 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5386596 0.88 CNR1 (0.37) HSD17B10KMT2AMEN1HPGDSMN1; SMN2
SCHEMBL4842136 0.88 CNR1 (0.35) HSD17B10
SCHEMBL5608706 0.84 CNR1 (0.36) KMT2AMEN1NPSR1NPC1RAB9A
SCHEMBL5399747 0.83 KMT2A (0.43) HSD17B10KMT2AMEN1POLBMAPT
SCHEMBL5384083 0.79 KMT2A (0.55) HSD17B10KMT2AMEN1POLBMAPT
SCHEMBL5391857 0.78 KMT2A (0.56) HSD17B10KMT2AMEN1POLBMAPT
SCHEMBL5386242 0.78 KMT2A (0.53) HSD17B10KMT2AMEN1POLBMAPT
SCHEMBL5382143 0.78 KMT2A (0.49) HSD17B10KMT2AMEN1POLBMAPT
SCHEMBL5377981 0.77 HSD17B10 (0.51) HSD17B10KMT2AMEN1POLBMAPT
SCHEMBL5384352 0.77 HSD17B10 (0.51) HSD17B10KMT2AMEN1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US claimed
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US claimed
US-7176210-B2 Cannabinoid receptor ligands and uses thereof PFIZER INC. (US) 2007-02-13 US disclosed
EP-1594872-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF Pfizer Products Inc. (US) 2005-11-16 EP disclosed
WO-2004069838-A1 CANNABINOID RECEPTOR LIGANDS AND USES THEREOF PFIZER PRODUCTS INC. (US) 2004-08-19 WO disclosed
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof PFIZER INC 2004-08-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040157838-A1 Cannabinoid receptor ligands and uses thereof CNR1, CNR2, GPR18 HSD17B10 2817/4885KMT2A 3816/4885MEN1 4394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.